Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.

about

Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.

Item

http://www.wikidata.org/entity/Q48193696

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Effect of dasatinib in a xenog ...... of its potential target EPHA2.

@en

Effect of dasatinib in a xenog ...... of its potential target EPHA2.

@nl

type

Item

label

Effect of dasatinib in a xenog ...... of its potential target EPHA2.

@en

Effect of dasatinib in a xenog ...... of its potential target EPHA2.

@nl

prefLabel

Effect of dasatinib in a xenog ...... of its potential target EPHA2.

@en

Effect of dasatinib in a xenog ...... of its potential target EPHA2.

@nl

P1476

Effect of dasatinib in a xenog ...... of its potential target EPHA2.

@en

P2093

H Tani

http://www.w3.org/2001/XMLSchema#string

K Ito

http://www.w3.org/2001/XMLSchema#string

K Tamura

http://www.w3.org/2001/XMLSchema#string

M Kobayashi

http://www.w3.org/2001/XMLSchema#string

R Miyamoto

http://www.w3.org/2001/XMLSchema#string

S Kurita

http://www.w3.org/2001/XMLSchema#string

P2860

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Emerging strategies for EphA2 receptor targeting for cancer therapeutics.

Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells.

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo.

EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation.

Establishment and biological characterization of canine histiocytic sarcoma cell lines.

Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.

Dasatinib Modulates Invasive and Migratory Properties of Canine Osteosarcoma and has Therapeutic Potential in Affected Dogs

EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma.

P304

e45-e48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JVP.12449

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Makoto Bonkobara

P577

2017-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28833247

http://www.w3.org/2001/XMLSchema#string

P921

xenograft